NCT02195232View on ClinicalTrials.gov

Cancer Associated Thrombosis and Isoquercetin (CATIQ)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

64

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2018

Study Completion Date

October 22, 2019

Conditions
Thromboembolism of Vein VTE in Colorectal CancerThromboembolism of Vein in Pancreatic CancerThromboembolism of Vein in Non-small Cell Lung Cancer
Interventions
DRUG

Isoquercetin

Trial Locations (11)

20422

Veterans Affair Medical Center, Washington D.C.

63110

Washington University in St. Louis, St Louis

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

95655

VA Northern California Health Care System, Sacramento

06450

VA Connecticut Healthcare System, West Haven

03909

York Hospital-Oncology Treatment Center, York Village

02130

Boston VA Healthcare System, Boston

02215

Beth Israel Deaconess Medical Center, Boston

02138

Mount Auburn Hospital, Waltham

02908

Providence VA Medical Center, Providence

05009

White River Junction VA Medical Center, White River Junction

All Listed Sponsors
collaborator

Quercegen Pharmaceuticals

INDUSTRY

collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

lead

Jeffrey Zwicker, MD

OTHER

NCT02195232 - Cancer Associated Thrombosis and Isoquercetin (CATIQ) | Biotech Hunter | Biotech Hunter